Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Mult Scler. 2013 Oct;19(12):1673-5. doi: 10.1177/1352458513498129. Epub 2013 Jul 25.
Balo's concentric sclerosis (BCS) is a rare demyelinating disorder of the central nervous system. The humanised monoclonal antibody alemtuzumab has shown efficacy in another demyelinating disorder, relapsing-remitting multiple sclerosis. We aimed to explore its efficacy in treatment-refractory BCS. A 52-year-old male with radiologically confirmed progressive BCS resistant to steroids, plasmapharesis and cyclophosphamide was administered a standard protocol of alemtuzumab. Treatment failed to slow his decline; he died 6 months after administration. Why alemtuzumab induced no clinical or radiological impact may be multifactorial. We review the evidence directing BCS therapy and propose the next steps for exploring this potentially fatal condition.
巴洛氏同心硬化症（BCS）是一种罕见的中枢神经系统脱髓鞘疾病。人源化单克隆抗体阿仑单抗在另一种脱髓鞘疾病——复发缓解型多发性硬化症中显示出疗效。我们旨在探索其在治疗抵抗性 BCS 中的疗效。一名 52 岁男性，影像学证实进行性 BCS 对类固醇、血浆置换和环磷酰胺耐药，给予阿仑单抗标准方案治疗。治疗未能减缓他的病情恶化；他在给药后 6 个月死亡。为什么阿仑单抗没有产生临床或影像学影响可能是多因素的。我们回顾了指导 BCS 治疗的证据，并提出了探索这种潜在致命疾病的下一步措施。
